Stock XVIVO XVIVO PERFUSION AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Xvivo Perfusion AB

Equities

XVIVO

SE0004840718

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:31 2024-04-26 am EDT 		5-day change 1st Jan Change
373 SEK +4.63% Intraday chart for Xvivo Perfusion AB +17.85% +13.20%
Apr. 24 Nordic Shares Declined Wednesday; Svenska Handelsbnkn Ser A Fell Furthest DJ
Apr. 24 Transcript : Xvivo Perfusion AB, Q1 2024 Earnings Call, Apr 24, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 4,522 9,018 8,215 5,459 10,379 11,749 - -
Enterprise Value (EV) 1 4,368 8,671 7,822 5,223 9,864 11,324 11,331 11,162
P/E ratio 895 x -195 x 995 x 295 x 107 x 159 x 73.6 x 44.3 x
Yield - - - - - - - -
Capitalization / Revenue 20.5 x 50.1 x 31.8 x 13.1 x 17.4 x 14.8 x 10.7 x 7.97 x
EV / Revenue 19.8 x 48.2 x 30.3 x 12.6 x 16.5 x 14.2 x 10.3 x 7.57 x
EV / EBITDA 152 x -555 x 569 x 108 x 122 x 75.9 x 39 x 25 x
EV / FCF -80.4 x -582 x -352 x 541 x - -223 x 114 x 100 x
FCF Yield -1.24% -0.17% -0.28% 0.18% - -0.45% 0.88% 1%
Price to Book 7.83 x 8.94 x 6.39 x 3.82 x 5.34 x 5.77 x 5.37 x 5.04 x
Nbr of stocks (in thousands) 26,600 28,719 29,499 29,832 31,499 31,499 - -
Reference price 2 170.0 314.0 278.5 183.0 329.5 373.0 373.0 373.0
Announcement Date 1/30/20 1/28/21 1/27/22 1/26/23 1/25/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 220.8 179.9 258.4 415.3 597.5 794.7 1,102 1,474
EBITDA 1 28.8 -15.64 13.76 48.58 80.54 149.2 290.2 445.7
EBIT 1 3.9 -45.68 -18.5 6.409 4.187 77.28 202.7 332.5
Operating Margin 1.77% -25.39% -7.16% 1.54% 0.7% 9.72% 18.39% 22.56%
Earnings before Tax (EBT) 1 5.29 -57.26 6.665 22.31 94.52 94.05 209.4 337.3
Net income 1 4.9 -43.74 8.152 18.43 91.82 78.69 165.2 265
Net margin 2.22% -24.32% 3.15% 4.44% 15.37% 9.9% 14.99% 17.98%
EPS 2 0.1900 -1.610 0.2800 0.6200 3.070 2.349 5.067 8.414
Free Cash Flow 1 -54.34 -14.9 -22.25 9.656 - -50.81 99.37 111.5
FCF margin -24.61% -8.28% -8.61% 2.33% - -6.39% 9.02% 7.56%
FCF Conversion (EBITDA) - - - 19.88% - - 34.24% 25.01%
FCF Conversion (Net income) - - - 52.4% - - 60.14% 42.07%
Dividend per Share 2 - - - - - - - -
Announcement Date 1/30/20 1/28/21 1/27/22 1/26/23 1/25/24 - - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 85.86 92.65 94.29 96.84 131.5 140.6 154.6 146.6 155.7 186 190.4 198.1 217.6 265 242
EBITDA 1 -0.096 14.69 14.4 5.904 13.58 24.89 17.22 18.93 20.75 36.89 33.51 35.84 43.82 64 78
EBIT 1 -8.3 4.624 4.138 -4.657 2.304 12.45 3.802 5.302 -16.12 19.94 15.64 17.47 24.95 40 50
Operating Margin -9.67% 4.99% 4.39% -4.81% 1.75% 8.85% 2.46% 3.62% -10.35% 10.72% 8.21% 8.82% 11.47% 15.09% 20.66%
Earnings before Tax (EBT) 1 10.24 6.189 10.38 2.992 2.751 16.56 11.44 0.954 65.56 30.01 16.25 17.51 25.24 40 50
Net income 1 12.19 4.765 7.53 5.398 0.734 14.18 6.886 2.284 68.47 22.78 12.84 18 20.22 32 40
Net margin 14.2% 5.14% 7.99% 5.57% 0.56% 10.08% 4.45% 1.56% 43.97% 12.25% 6.74% 9.08% 9.29% 12.08% 16.53%
EPS 2 0.4100 0.1600 0.2600 0.1800 0.0200 0.4800 0.2300 0.0800 2.170 0.7200 0.4991 0.5268 0.7625 1.010 1.270
Dividend per Share 2 - - - - - - - - - - 6.000 7.000 8.000 - -
Announcement Date 1/27/22 4/25/22 7/13/22 10/27/22 1/26/23 4/24/23 7/13/23 10/24/23 1/25/24 4/24/24 - - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 154 347 393 237 515 425 418 587
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -54.3 -14.9 -22.3 9.66 - -50.8 99.4 112
ROE (net income / shareholders' equity) 0.88% -3.83% 2.09% 1.36% 5.44% 3.83% 7.65% 11.3%
ROA (Net income/ Total Assets) - - - - 4.69% 3.4% 7.1% 11.3%
Assets 1 - - - - 1,957 2,315 2,327 2,345
Book Value Per Share 2 21.70 35.10 43.60 47.90 61.70 64.70 69.40 74.00
Cash Flow per Share 2 1.100 -2.830 -0.4200 - - 4.500 5.300 9.700
Capex 1 83.8 64.7 10.2 18.2 - 163 142 160
Capex / Sales 37.97% 35.96% 3.95% 4.38% - 20.51% 12.89% 10.86%
Announcement Date 1/30/20 1/28/21 1/27/22 1/26/23 1/25/24 - - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Xvivo Perfusion AB

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
373 SEK
Average target price
408 SEK
Spread / Average Target
+9.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
XVIVO PERFUSION AB Stock Xvivo Perfusion AB
+13.20% 1.07B
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. XVIVO Stock
  4. Financials Xvivo Perfusion AB